Agilent agreed to acquire Biocare Medical for $950 million in cash, adding immunohistochemistry (IHC), in‑situ hybridization (ISH), FISH assays and a library of over 300 specialized antibodies to its pathology portfolio. Agilent said the deal strengthens its position in diagnostics and surgical pathology workflows. The acquisition accelerates Agilent’s strategy to provide end‑to‑end pathology solutions and supports demand for companion diagnostics and advanced tissue‑based assays. The transaction is expected to close subject to customary approvals and will be integrated into Agilent’s existing life‑sciences and diagnostics offerings. Market implication: the move underscores ongoing consolidation among instrumentation and reagents providers as diagnostic testing and precision pathology become central to oncology drug development and clinical adoption.